Key result
Empagliflozin consistently improved LVEF by 1.5%-5.7% and reduced HF hospitalizations, whereas colchicine reduced inflammatory markers but had inconsistent cardiovascular efficacy.
Why the study?
Patients with reduced LVEF after STEMI remain at high risk for HF, adverse remodeling, and cardiovascular mortality, prompting the evaluation of empagliflozin and colchicine as adjunctive therapies.
Do empagliflozin and colchicine improve outcomes in patients with STEMI who develop reduced LVEF, and how do their effects compare?
Systematic Review
Do empagliflozin and colchicine improve outcomes in patients with STEMI who develop reduced LVEF, and how do their effects compare?
Empagliflozin provides consistent benefits in improving ventricular function and reducing heart failure hospitalizations in post-STEMI patients with reduced LVEF, while colchicine demonstrates inconsistent cardiovascular efficacy and notable tolerability concerns.
Answers are grounded in this paper and cite their sources.
Empagliflozin warrants consideration post-STEMI with reduced LVEF; confirms consistent benefits while challenging colchicine's inconsistent effects.
Patients with reduced left ventricular ejection fraction (LVEF) following ST-elevation myocardial infarction (STEMI) are at a high risk for heart failure (HF), adverse ventricular remodeling, and cardiovascular mortality. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and colchicine, an anti-inflammatory agent, have been proposed as adjunctive therapies to mitigate post-myocardial infarction (MI) complications. A systematic review of randomized controlled trials (RCTs) published in English between January 2015 and June 2025 was conducted using PubMed, Embase, and Cochrane Library. Fourteen RCTs were included. Risk of bias assessment using Cochrane RoB 2.0 classified five studies as low risk and eight as of some concern. Evaluating empagliflozin or colchicine in post-STEMI patients with LVEF <45% was conducted. Key outcomes included changes in LVEF, N-terminal pro-B-type natriuretic peptide (NT-proBNP), HF hospitalization, mortality, inflammatory biomarkers (CRP, creatine kinase-myocardial band (CK-MB)), and safety profiles. The Cochrane Risk of Bias 2.0 was used for quality assessment, and data were synthesized thematically. Visual summaries were generated using the robvis tool. The review indicated that empagliflozin consistently improved LVEF by 1.5%-5.7%, reduced NT-proBNP by approximately 15%, and lowered HF hospitalization risk, though it did not significantly reduce all-cause mortality. Colchicine reduced inflammatory markers (CRP, CK-MB) and recurrent ischemic events, but its effects on LVEF and HF outcomes were inconsistent. Colchicine was also associated with a higher incidence of gastrointestinal side effects and an increased risk of left ventricular thrombus formation. Empagliflozin showed consistent benefits in improving ventricular function and reducing HF hospitalizations after STEMI in patients with type 2 diabetes and should be prioritized in this setting. Colchicine provided potential anti-inflammatory and ischemic protection but demonstrates inconsistent cardiovascular efficacy and notable tolerability concerns. Further high-quality RCTs are required to clarify its role.
No takes yet. Share an insight, caveat, or question.
Baadu et al. (2025) conducted a systematic review in ST-elevation myocardial infarction (STEMI) with reduced left ventricular ejection fraction. Empagliflozin or Colchicine vs. Placebo or standard therapy was evaluated on Heart failure hospitalization, cardiac remodeling, and mortality. Empagliflozin consistently improved LVEF by 1.5%-5.7% and reduced HF hospitalizations, whereas colchicine reduced inflammatory markers but had inconsistent cardiovascular efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: